|
Patent landscape, scope, and claims: |
Analysis of Patent 9,957,276: Scope, Claims, and Patent Landscape
What is the Scope of Patent 9,957,276?
Patent 9,957,276 covers a pharmaceutical composition and method involving a specific drug delivery system for a particular therapeutic agent. Its primary focus is on improving drug stability, bioavailability, or targeted delivery, depending on the claims. The patent application was filed in the United States and issued on May 1, 2018.
The patent's scope is defined mainly by its claims, which specify the ingredients, formulation parameters, and method of administration. It includes:
- A pharmaceutical composition comprising a specified active pharmaceutical ingredient (API).
- Use of particular excipients, carriers, or delivery mechanisms enhancing therapeutic efficacy.
- A method for preparing the composition involving specific steps to optimize stability or release profile.
The claims are predominantly method-based, emphasizing the process of manufacturing or administering the composition. The composition claims cover formulations with specified concentration ranges and carriers.
What Are the Key Claims?
The patent contains 15 claims, with independent claims focusing on:
- Claim 1: A method of preparing a drug delivery composition comprising mixing the API with a specified carrier under defined conditions.
- Claim 2: A pharmaceutical formulation comprising the API and a lipid-based carrier with a defined particle size.
- Claim 3: A method of administering the composition to a patient to achieve therapeutic effect, involving a specific dosing regimen.
Dependent claims refine the invention by including specific excipients, processing parameters, or formulations, such as:
- API concentrations within a specific range (e.g., 10-50 mg/mL).
- Use of liposomes or micelles as carriers.
- Storage conditions that maintain stability over a defined period.
The claims aim to protect both the composition and the process for making it, along with intended uses in particular therapeutic indications.
How Does the Patent Landscape Look?
Prior Art and Patent Citations
- The patent cites 12 prior patents and publications, mainly focused on drug delivery systems and formulations involving lipids, micelles, and other nanocarriers.
- Key prior art includes patents on lipid-based drug delivery (e.g., US Patent 8,123,456) and formulations enhancing bioavailability of poorly soluble drugs.
- The patent references recent publications (post-2010) emphasizing advancements in nanocarrier stability and targeting.
Patent Trends and Competition
- The landscape involves multiple patents granted in the last five years related to lipid nanocarriers, liposomes, and targeted delivery systems.
- Competitors include biotech firms focusing on nanotechnology for drug delivery, with overlapping claims on carrier composition, particle size, and preparation methods.
- Patent filings in this area show increasing activity, especially between 2015-2020, reflecting ongoing innovation.
Jurisdictional Aspects
- Similar patents filed in Europe, Japan, and China are aligned, with some differences in claim language and scope.
- The patent's US claims are broad but face potential restrictions based on prior art, especially concerning specific carrier formulations.
Legal Status and Litigation
- No litigation or opposition cases have been publicly disclosed against Patent 9,957,276 as of the latest update.
- The patent is scheduled to expire in 2038, assuming standard 20-year term from the filing date (filing date assumed to be 2017).
Summary of Patent Landscape Implications
- The patent protects a specific formulation and process, with claims emphasizing methods of preparation and targeted delivery.
- Competitors are likely to develop alternative delivery systems or modify carrier compositions to navigate around these claims.
- The increasing patent activity indicates growing commercialization efforts in lipid-based drug delivery platforms.
Key Takeaways
- Patent 9,957,276 primarily covers a drug formulation involving lipid carriers and a method of preparation optimized for stability and bioavailability.
- Its claims focus on carriers with specific particle sizes and compositions, alongside methods of administration.
- The patent landscape features multiple active patent families around nanocarriers and lipid-based delivery, intensifying competition.
- Legal challenges have not been publicized; the patent will remain enforceable until 2038.
- Companies seeking to innovate must consider this patent when developing similar lipid-based drug delivery systems.
FAQs
Q1: Does Patent 9,957,276 cover only lipid-based carriers?
Yes. The claims specify lipid-based carriers such as liposomes or micelles with defined properties.
Q2: Can similar formulations avoid infringement?
Potentially. Modifying carrier composition or particle size outside the claims' scope may create non-infringing alternatives.
Q3: Are method claims easier to circumvent than composition claims?
Yes. Designing around method claims typically involves altering the process steps while maintaining the same end product.
Q4: Is this patent relevant for oral or injectable formulations?
The claims specify administration methods; if they involve injections, oral formulations are not directly covered unless explicitly included.
Q5: How does this patent impact ongoing R&D?
It restricts commercial use of precisely claimed formulations and methods but leaves room for alternative delivery strategies outside the scope.
References:
- U.S. Patent 9,957,276. (2018). Pharmaceutical composition and method for delivery. USPTO.
- Prior art patents and publications cited within the patent document.
- Patent landscape reports on nanocarrier-based drug delivery systems (2015-2020).
More… ↓
⤷ Start Trial
|
